Blocking these TLR drivers is expected to disrupt the pathological re-enforcing cycle of inflammation and neurodegeneration leading to slowing of disease progression and improvement of symptoms. Eos ...
Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with Solu Therapeutics (Solu) and is pleased to announce the ...